Asia's First Clinical Validated Multi-Cancer Blood Test
Gene Solutions announced that its SPOT-MAS 10 test has become the first multi-cancer screening blood test in Asia to complete large prospective cohort validation, as published in BMC Medicine. This milestone marked a major advancement, enabling large-scale, non-invasive early cancer detection. In addition to SPOT-MAS 10, which can detect 10 types of cancer (*), Gene Solutions also launched SPOT-MAS Lung, a blood cancer screening test that integrates multiple Artificial Intelligence techniques to analyze circulating tumor DNA deprived from lung cells. This option offers a more precise, non-invasive and affordable test designed for lung cancer screening.
(*) including breast, lung, stomach, liver – bile duct, head & neck, colon, ovary, pancreatic, esophageal, and endometrium.
Gene Solutions is a pioneer in Asia in using blood samples containing DNA fragments to detect the presence of certain diseases, particularly in relation to maternity and cancer. Their technology is on par with the leading U.S. based competitors but delivered at a fraction of the price in Southeast Asia. Gene Solutions currently offers three types of innovative products, including Non-invasive prenatal testing (NIPT) for pregnant women, early cancer detection tests (SPOT-MAS 10 and SPOT-MAS single test), and tests for cancer treatment and remission (K-Track and K-4care).